Gosset Ownership
Private
Employees
~3
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
TianTi Biotherapeutics General Information
TianTi Biotherapeutics has not yet reported clinical results. The company’s pipeline consists of preclinical and discovery-stage antibody therapeutics targeting oncology and rare diseases. Their proprietary AbLink™ platform enables deep mining of the natural immune repertoire to identify rare therapeutic antibody candidates with high functional potential. No clinical trial data or approvals have been reported as of May 2025.
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
TianTi Biotherapeutics Funding
No funding data available
To view TianTi Biotherapeutics's complete valuation and funding history, request access »